AU2016363113A1 - Monitoring treatment or progression of myeloma - Google Patents

Monitoring treatment or progression of myeloma Download PDF

Info

Publication number
AU2016363113A1
AU2016363113A1 AU2016363113A AU2016363113A AU2016363113A1 AU 2016363113 A1 AU2016363113 A1 AU 2016363113A1 AU 2016363113 A AU2016363113 A AU 2016363113A AU 2016363113 A AU2016363113 A AU 2016363113A AU 2016363113 A1 AU2016363113 A1 AU 2016363113A1
Authority
AU
Australia
Prior art keywords
kras
nras
individual
cell
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016363113A
Other languages
English (en)
Inventor
Sridurga MITHRAPRABHU
Andrew Spencer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905013A external-priority patent/AU2015905013A0/en
Application filed by Individual filed Critical Individual
Publication of AU2016363113A1 publication Critical patent/AU2016363113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2016363113A 2015-12-03 2016-12-02 Monitoring treatment or progression of myeloma Abandoned AU2016363113A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015905013 2015-12-03
AU2015905013A AU2015905013A0 (en) 2015-12-03 Monitoring treatment or progression of myeloma
AU2016903019 2016-08-01
AU2016903019A AU2016903019A0 (en) 2016-08-01 Monitoring treatment or progression of myeloma (2)
PCT/AU2016/051191 WO2017091865A1 (en) 2015-12-03 2016-12-02 Monitoring treatment or progression of myeloma

Publications (1)

Publication Number Publication Date
AU2016363113A1 true AU2016363113A1 (en) 2018-06-07

Family

ID=58796005

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016363113A Abandoned AU2016363113A1 (en) 2015-12-03 2016-12-02 Monitoring treatment or progression of myeloma

Country Status (8)

Country Link
US (1) US20180282820A1 (enExample)
EP (1) EP3384050A4 (enExample)
JP (2) JP2018537128A (enExample)
KR (1) KR20180088690A (enExample)
CN (1) CN108603232A (enExample)
AU (1) AU2016363113A1 (enExample)
CA (1) CA3007426A1 (enExample)
WO (1) WO2017091865A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
DK3294906T3 (en) 2015-05-11 2024-08-05 Natera Inc Methods for determining ploidy
DK3443119T3 (da) 2016-04-15 2022-05-23 Natera Inc Fremgangsmåde til bestemmelse af lunge cancer
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
JP2020524519A (ja) 2017-06-20 2020-08-20 ザ メディカル カレッジ オブ ウィスコンシン，インコーポレイテッドＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 全セルフリーｄｎａによる移植合併症リスクの評価
CN111213209A (zh) 2017-10-12 2020-05-29 南托米克斯有限责任公司 根据生物体液的评估用癌症评分和反应预测
CN107881233A (zh) * 2017-10-31 2018-04-06 天津协和华美医学诊断技术有限公司 一种检测骨髓瘤相关基因群的检测试剂盒
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
WO2019207439A1 (en) * 2018-04-23 2019-10-31 Inivata Ltd. Method for predicting and monitoring response to an immune checkpoint inhibitor
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN112601824A (zh) 2018-08-08 2021-04-02 英威达有限公司 使用可变重复多重pcr测序的方法
EP3874042A4 (en) * 2018-10-29 2023-06-28 Molecular Stethoscope, Inc. Characterization of bone marrow using cell-free messenger-rna
AU2019372123A1 (en) * 2018-10-30 2021-06-17 Molecular Stethoscope, Inc. Cell-free RNA library preparations
WO2020131955A1 (en) * 2018-12-17 2020-06-25 The Medical College Of Wisconsin, Inc. Assessing risk with total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US20210087638A1 (en) * 2019-09-23 2021-03-25 Dana-Farber Cancer Institute, Inc. Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
GB2623904B (en) * 2019-11-06 2024-07-24 Univ Leland Stanford Junior Methods and systems for analyzing nucleic acid molecules
FR3105738B1 (fr) * 2019-12-26 2024-01-05 P M B Dispositif d’irradiation collaboratif
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009281969A1 (en) * 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-RNA-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
CA2855368A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CN113337604A (zh) * 2013-03-15 2021-09-03 莱兰斯坦福初级大学评议会 循环核酸肿瘤标志物的鉴别和用途
HK1222209A1 (zh) * 2013-10-19 2017-06-23 Trovagene, Inc. 隨時間檢測疾病中的突變

Also Published As

Publication number Publication date
KR20180088690A (ko) 2018-08-06
EP3384050A1 (en) 2018-10-10
CA3007426A1 (en) 2017-06-08
EP3384050A4 (en) 2019-07-31
US20180282820A1 (en) 2018-10-04
JP2018537128A (ja) 2018-12-20
WO2017091865A1 (en) 2017-06-08
CN108603232A (zh) 2018-09-28
JP2022000059A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
US20180282820A1 (en) Monitoring treatment or progression of myeloma
US12139763B2 (en) Methods for subtyping of lung adenocarcinoma
US11111541B2 (en) Diagnostic MiRNA markers for Parkinson's disease
US10457988B2 (en) MiRNAs as diagnostic markers
CN104981548A (zh) 用于阿尔茨海默氏病的诊断性miRNA标志物
CN105518151A (zh) 循环核酸肿瘤标志物的鉴别和用途
AU2021291586A1 (en) Multimodal analysis of circulating tumor nucleic acid molecules
US20170130269A1 (en) Diagnosis of neuromyelitis optica vs. multiple sclerosis using mirna biomarkers
CN110741096A (zh) 用于检测循环肿瘤dna的组合物和方法
WO2017112738A1 (en) Methods for measuring microsatellite instability
KR101828125B1 (ko) 다발성 경화증에서의 진단 miRNA 프로파일
EP3775274B1 (en) Detection method of somatic genetic anomalies, combination of capture probes and kit of detection
JP2021505143A (ja) 多血小板血漿サンプルからの核酸の検出
EP4399329A1 (en) Method of detecting and quantifying genomic and gene expression alterations using rna
KR102156699B1 (ko) 소음인 판별용 조성물
JP2026505350A (ja) 尿中の腎同種移植片拒絶反応遺伝子を同定するための方法およびそれらの測定を行うことの有用性
Tsui et al. Applications of circulating DNA analysis in personalized medicine
CN118139987A (zh) 用于cfrna和cftna靶向ngs测序的组合物和方法
EP3696283B1 (en) Molecular markers in bladder cancer
BR122020011728B1 (pt) Método para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide com citologia indeterminada para cirurgia diagnóstica, e para prognosticar risco de malignidade em um sujeito com resultados de citologia para paaf da tireoide inconclusivos, e, kit para detectar pelo menos uma mutação em genes relacionados ao câncer de tireoide em uma amostra ffpe da tireoide ou uma amostra paaf da tireoide, e para detectar pelo menos um produto de fusão genética em uma amostra ffpe da tireoide ou uma amostra paaf da tireoide
BR112018013430B1 (pt) Métodos para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide, e, para prognosticar risco de malignidade

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application